Top

Supportive Care in Cancer

Published in:

01-02-2017 | Letter to the editor

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?

Authors: Vittorio Fusco, Alberto Bedogni, Alfredo Addeo, Giuseppina Campisi

Published in: Supportive Care in Cancer | Issue 2/2017

Excerpt

To the Editor, …

Stopeck AT, Fizazi K, Body JJ, et al. (2015) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447–455. doi:10.1007/s00520-015-2904-5 CrossRefPubMedPubMedCentral

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28:5132–5139. doi:10.1200/JCO.2010.29.7101 CrossRefPubMed

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822. doi:10.1016/S0140-6736(10)62344-6 CrossRefPubMedPubMedCentral

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587CrossRefPubMed

Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952CrossRefPubMed

Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2008) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. the experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145. doi:10.1093/annonc/mdn526 CrossRefPubMed

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362. doi:10.1200/JCO.2009.21.9584 CrossRefPubMed

Bozas G, Allgar V, Greenwood G, et al (2011). Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid (abstract e15116). J Clin Oncol. Available at: http://meetinglibrary.asco.org/content/82466-102.

Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F (2013) Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 71:1532–1540. doi:10.1016/j.joms.2013.03.019 CrossRefPubMed

10.

Saad F, Brown JE, Poznak CV, et al. (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347. doi:10.1093/annonc/mdr435 CrossRefPubMed

11.

Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65(3):369–376CrossRef

12.

Junquera L, Gallego L (2008) Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 66:1516–1517. doi:10.1016/j.joms.2008.02.012 CrossRefPubMed

13.

Ruggiero SL, Dodson TB, Assael LA, et al. (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67(suppl 1):2–12PubMed

14.

Colella G, Campisi G, Fusco V (2009) American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws—2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67:2698–2699. doi:10.1016/j.joms.2009.07.097 CrossRefPubMed

15.

Otto S, Marx RE, Tröltzsch M, Ristow O, Ziebart T, Al-Nawas B, Groetz KA, Ehrenfeld M, Mercadante V, Porter S, Bedogni A, Campisi G, Fusco V, Dayisoylu E, Fliefel R, Herlofson BB, Pautke C, Kwon T-G, Fedele S (2015) Comments on “Diagnosis and Management of Osteonecrosis of the Jaw: a systematic review and international consensus”. J Bone Miner Res 30:1113–1115. doi:10.1002/jbmr.2525 CrossRefPubMed

16.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—20 14 update. J Oral Maxillofac Surg 72:1938–1956. doi:10.1016/j.joms.2014.04.031 CrossRefPubMed

17.

Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, Angeli A, Bertetto O (2011) Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol 29(17):521–522. doi:10.1200/JCO.2011.35.1551 Epub 2011 May 2CrossRef

18.

Setabutr D, Hales NW, Krempl GA (2010) Necrotizing fasciitis secondary to bisphosphonate-induced osteonecrosis of the jaw. Am J Otolaryngol 31:127–129. doi:10.1016/j.amjoto.2008.11.002 CrossRefPubMed

19.

Kaehling C, Streckbein P, Schmermund D, Henrich M, Burchert D, Gattenloehner S, Howaldt HP, Wilbrand JF (2014) Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw. J Craniomaxillofac Surg 42:1203–1206. doi:10.1016/j.jcms.2014.02.009 CrossRefPubMed

20.

Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057CrossRefPubMed

21.

Berenson JR, Hillner BE, Kyle RA, et al. (2002) American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719–3736CrossRefPubMed

22.

Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047–1053CrossRefPubMed

23.

Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K (2007) American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464–2472CrossRefPubMed

24.

Durie BG (2007) Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 82:516–517CrossRefPubMed

25.

Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi GN, Jonat W, Lipton A, Monnier A, Paterson AH, Rizzoli R, Saad F, Thürlimann B (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432CrossRefPubMed

26.

Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow BE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Van Roenn JH (2011) American Society of Clinical Oncology. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221–1227. doi:10.1200/JCO.2010.32.5209 CrossRefPubMed

Title: Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?
Authors: Vittorio Fusco
Alberto Bedogni
Alfredo Addeo
Giuseppina Campisi
Publication date: 01-02-2017
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 2/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-016-3147-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2017

Determining best methods to screen for religious/spiritual distress

Photobiomodulation therapy in the management of chronic oral graft-versus-host disease

Impact of enhanced recovery program on patients with esophageal cancer in comparison with traditional care

A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer

A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions

Keynote webinar | Spotlight on antibody–drug conjugates in cancer